These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25532798)

  • 1. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.
    Sakurai Y; Kolokoltsov AA; Chen CC; Tidwell MW; Bauta WE; Klugbauer N; Grimm C; Wahl-Schott C; Biel M; Davey RA
    Science; 2015 Feb; 347(6225):995-8. PubMed ID: 25722412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin inhibits Ebola pseudovirus infection in cell culture.
    Wang Y; Cui R; Li G; Gao Q; Yuan S; Altmeyer R; Zou G
    Antiviral Res; 2016 Jan; 125():1-7. PubMed ID: 26585243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a broad-spectrum antiviral with activity against Ebola virus.
    Aman MJ; Kinch MS; Warfield K; Warren T; Yunus A; Enterlein S; Stavale E; Wang P; Chang S; Tang Q; Porter K; Goldblatt M; Bavari S
    Antiviral Res; 2009 Sep; 83(3):245-51. PubMed ID: 19523489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
    Wu W; Liu S
    Curr Top Med Chem; 2017; 17(3):361-370. PubMed ID: 27572081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Small Molecule Entry Inhibitors of Ebola Virus.
    Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.
    Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM
    Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
    Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
    Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
    Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease.
    Schafer A; Cheng H; Lee C; Du R; Han J; Perez J; Peet N; Manicassamy B; Rong L
    Curr Med Chem; 2018; 25(38):5177-5190. PubMed ID: 29032747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
    Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
    Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of treatment strategies to combat Ebola and Marburg viruses.
    Paragas J; Geisbert TW
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug targets in infections with Ebola and Marburg viruses.
    Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
    Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
    Beck S; Henß L; Weidner T; Herrmann J; Müller R; Chao YK; Grimm C; Weber C; Sliva K; Schnierle BS
    Antiviral Res; 2016 Aug; 132():85-91. PubMed ID: 27241689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ebola virus disease.
    Kilgore PE; Grabenstein JD; Salim AM; Rybak M
    Pharmacotherapy; 2015 Jan; 35(1):43-53. PubMed ID: 25630412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doctors trial amiodarone for Ebola in Sierra Leone.
    Turone F
    BMJ; 2014 Nov; 349():g7198. PubMed ID: 25429872
    [No Abstract]   [Full Text] [Related]  

  • 20. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
    Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
    Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.